Key facts
- This page summarizes Darren Charlton Smith's Form 4 filing for Telix Pharmaceuticals Ltd (TLX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 Apr 2026, 19:14.
Darren Charlton Smith - 29 Mar 2026 Form 4 Insider Report for Telix Pharmaceuticals Ltd (TLX)
- Reporting relationship
- Group Chief Financial Officer
- Issuer ticker
- TLX
- Reported as of
- 29 Mar 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Apr 2026, 19:14:36 UTC
- Prior SEC filing
- 01 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Oliver Newman, on behalf of Mr. Darren Smith, Group CFO
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Darren Charlton Smith filed Form 4 for Telix Pharmaceuticals Ltd (TLX) on 01 Apr 2026.
Change
- Previous filing in this sequence was filed on 01 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002122447
Primary reporting owner
Smith Darren Charlton
- Relationship
- Group Chief Financial Officer
- Address
- C/O TELIX PHARMACEUTICALS LTD, 55 FLEMINGTON RD, NORTH MELBOURNE, AUSTRALIA
- Signature
- /s/ Oliver Newman, on behalf of Mr. Darren Smith, Group CFO
- Signature date
- 01 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TLX
transaction
Ordinary Shares
Options Exercise
- Transaction value
- Shares
- +1,111
- Change %
- +10%
- Price
- $0.000000*
- Shares after
- 11,921
- Date
- 29 Mar 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TLX
transaction
Derivative
Share Rights
Options Exercise
- Transaction value
- Shares
- -1,111
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 29 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 1,111
- Exercise price
- $0.000000
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The share rights (SRs) were granted on January 1, 2025 and became vested and exercisable on March 5, 2026.